Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for ...

With increasing awareness about the need to manage obesity—a global epidemic—launch of weight-loss injections in India and public demand for tailored treatment, hospitals in Delhi-NCR are stepping up ...

Obesity in India is a family problem, not an individual one, with sedentary lifestyles and unhealthy diets leading to weight ...

A recent study reveals that nearly 20% of Indian households have all adults classified as overweight, while 10% are obese.

According to a study in The Lancet, over 14.4 million children in India are obese, making the country home to the ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...

Kombucha's popularity in India grows, but scientific evidence lags; new study explores gut microbiome effects for health.

Eli Lilly receives approval for Mounjaro in prefilled Kwikpen as competition intensifies in India's weight-loss drug market ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...